Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OM Pharma

Latest From OM Pharma

Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches

October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.

Financing Commercial

Business & Technology Briefs (06/2007)

Brief summaries of recent product and company developments in the device industry, including Aspect Medical's brain monitoring technology, Warburg's bid for Bausch & Lomb, and Frazier Healthcare Venture's investment in publicly-traded Endocare.

Dealmaking (06/02)

Summarizing the month in European dealmaking.


...are being developed covering excipient manufacturers and computer vendors as part of a pharmaceutical industry push to broaden quality assurance. Suppliers and users are cooperating on the two auditing programs designed to standardize auditing practices and reduce the overall resource burden. To complement its new auditing program, the International Pharmaceutical Excipients Council is developing a series of excipient guides based on its GMP document that will address -- auditing manufacturers and distributors -- handling manufacturing changes -- profiling impurities n n formulating certificates of analysis -- and developing specifications. The association PDA is launching a "shared" auditing program for computer suppliers similar to the IPEC effort. A new guide on cooperative manufacturing arrangements from CBER will expand the use of contract manufacturing and create new communication and auditing challenges for participating biologics companies. [A discussion by a DuPont official of the firm’s auditing program for foreign contract manufacturers begins on p. 15.]
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • OM Pharma
  • Senior Management
  • Gerard Normier, Dir., R&D
    Antoine Zermatten, Dir., Bus. Dev.
    Winston Kenzey, Dir., Fin.
    Christophe Richard, Pres.
    Reto Baumann, Dir., Mktg.
  • Contact Info
  • OM Pharma
    Phone: (41) 2278 31111
    Rue du Bois-du-Lan 22
    1217 Meyrin,